Development Strategy

MicroIslet has licensed patented technologies from Duke University Medical Center for the isolation, culture, cryopreservation, and immuno-protection (microencapsulation) of insulin-producing islet cells.

The company's near term development strategy includes:

• Optimize the proprietary microencapsulated porcine islet technology.
  
  
• Conduct preclinical animal studies to support regulatory filings for MicroIslet-P™.
  
  
• Plan pilot xenotransplantation human clinical studies employing MicroIslet's encapsulation technology in a yet to be determined foreign country.
  
  
• Conduct or sponsor research to expand MicroIslet's portfolio of cell source and cell delivery systems. This includes research into stem cells, cell proliferation lines, and macroencapsulation devices.

back to top